

Singular Health Group Ltd: SHG

ASX Announcement

17th November 2023

Singular Health Receives Commitment For \$850,000 From CG1 Ventures

17th November 2023 – Medical technology company Singular Health Group Limited (ASX: SHG, “Singular Health”, or the “Company”) is pleased to announce that it has received a binding commitment from CG1 Ventures to take up the full \$850,000 placement at 5.5 cents per share as previously announced on 16 August 2023.

Following the results of Singular Health’s Annual General Meeting held on Friday 10 November 2023, at which the shares and options to be issued to CG1 Ventures (“CG1 Ventures”) were approved, the Company is very pleased to have received a binding commitment from CG1 Ventures for the full AUD\$850,000 placement.

As mutually agreed, CG1 Ventures shall pay Singular Health the full amount of \$850,000 through a series of monthly instalments until 6 February 2024. Singular has the ability to utilise the funds as they are received, and the shares and options for the placement shall only be issued at such time that CG1 Ventures has paid the committed funds in full, anticipated prior to 6 February 2024. In the event that CG1 Ventures does not pay the full subscription amount of \$850,000, any funds paid by CG1 are non-refundable by Singular and no shares and or options are to be issued pro-rata for the amounts paid by CG1. The terms of the subscription agreement not varied and as previously announced continue to apply.

As the venture arm of CG1 Solutions LLC, Singular Health’s Master Distributor in the United States, this binding commitment to take up the full allocation of the placement with highly favourable payment terms is a testament to the confidence of the Company’s Master Distributor in the commerciality of the Company’s medical software in the world’s largest medical market.

Singular Health’s Chief Executive Officer and Managing Director, Denning Chong, said:

“With the recent receipt of sizeable R&D refunds, and now CG1 Venture’s commitment to the full placement at a 34% premium to our last closing price, Singular Health is well positioned to focus on the completion of sales in the United States through our highly supportive Master Distributor and Partner, CG1 Solutions.”

Managing Partner of CG1 Ventures and CG1 Solutions, Mr Edwin Rivera, said:

“CG1 Ventures is highly excited by the potential of Singular Health’s 3Dicom software and medical file transfer protocol, and we look forward to expanding our footprint here in the United States as we continue to progress with high value enterprise sales with respected institutions that will form the foundation of future success.”

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary + 61 8 9322 7600

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health's 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices. It also provides hardware solutions as an official reseller of the 3D Systems, Kings 3D, and DyeMansion brands in the Australian and New Zealand markets.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>